Viking Therapeutics

Clinical‑stage biopharma Viking Therapeutics is developing oral tissue‑selective TRβ agonist VK2809 for NASH/NAFLD, plus a Phase II AR‑modulator VK5211 for post‑fracture rehabilitation, and a Phase‑IIb diabetes candidate VK0612, positioned for rapid pipeline expansion.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 50
HQ: San Diego

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
VKTX	Viking Therapeutics Cap: 3.6B	EQUITY	NCM	USD	US92686J1060	Active	📈